Andréia Latanza Gomes Mathez1, Patrícia Teófilo Monteagudo 1,
Ieda T herezinha do Nascimento Verreschi1 & Magnus Régios Dias-da-Silva 1,2
Turner Syndrome (TS) is associated with an increased risk of cardiovascular and metabolic
complications. Furthermore, TS women need hormone replacement therapy (HRT), of which progestins
can influence body weight. We aimed to analyze the metabolic and weight profile in a cohort of 111
TS women. They started receiving estrogen at 15.8 (±3.6) years old, with no change in hypertension,
dysglycemia, and dyslipidemia incidence but with a tendency to increase overweight (p = 0.054). As the
first used type of progestin, most had received cycles of 10 days per month of medroxyprogesterone
(MPA) or levonorgestrel (LNG), then shifted to micronized progesterone (MP), which has currently
become the most used one. By multiple linear regression analysis, we found that the prolonged use of
MPA, LNG, or MP showed no metabolic change except for weight gain. The percentage of annual BMI
increment was positive for all progestins used in TS women (MPA 2.2 ± 2.2; LNG 0.2 ± 1.2; and MP
2.2 ± 2.6 kg/m2), but LNG seemed to best prevent on weight gain over time (p < 0.05). In conclusion,
metabolic comorbidities are prevalent in TS even before the HRT regimen, and LNG performed better
on less weight gain than MPA and MP in our cohort of the TS population.